Holen Sie sich die Stockscreener-App
18.37
4.67%
-0.90
Handel nachbörslich:
18.37
Schlusskurs vom Vortag:
$19.27
Offen:
$19.29
24-Stunden-Volumen:
974.27K
Relative Volume:
1.05
Marktkapitalisierung:
$2.20B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-8.5442
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
-8.29%
1M Leistung:
+15.83%
6M Leistung:
-23.84%
1J Leistung:
-15.97%
1-Tages-Spanne:
$18.27
$19.82
1-Wochen-Bereich:
$17.49
$20.91
52-Wochen-Spanne:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.37 | 2.20B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - Stock Titan
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Invesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co. - Defense World
A closer look at NewAmsterdam Pharma Company NV (NAMS)’s stock price trends - uspostnews.com
Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
(NAMSW) Trading Report - news.stocktradersdaily.com
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Head to Head Survey: NewAmsterdam Pharma (NASDAQ:NAMS) vs. Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Is NewAmsterdam Pharma Company NV (NASDAQ: NAMS) A Good Investment Now? - Stocksregister
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares By Investing.com - Investing.com Canada
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - The Manila Times
NewAmsterdam Pharma adds Adele Gulfo to its Board By Investing.com - Investing.com South Africa
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares - Investing.com Australia
NewAmsterdam Pharma adds Adele Gulfo to its Board - Investing.com
Blockbuster Drug Veteran Who Led $12B Pfizer Unit Joins NewAmsterdam Board Before Critical Launch - Stock Titan
Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
KLP Kapitalforvaltning AS Purchases Shares of 6,000 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low – Here’s Why - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Average Price Target from Analysts - Defense World
Where are the Opportunities in (NAMSW) - news.stocktradersdaily.com
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):